Yes, Lurbinectedin can be used in combination therapies.
Lurbinectedin is a novel selective inhibitor of oncogenic transcription. It has been shown to have antitumor activity in a range of tumor models, including small cell lung cancer, ovarian cancer, and breast cancer. [3]
In recent studies, Lurbinectedin has been used in combination with other drugs to treat various types of cancer. For example, a study published in the Journal of Clinical Oncology found that Lurbinectedin in combination with doxorubicin was effective in treating patients with small cell lung cancer. [2] The study showed that the combination therapy resulted in a higher response rate and longer progression-free survival compared to doxorubicin alone.
Another study published in the Annals of Oncology found that Lurbinectedin in combination with irinotecan was effective in treating patients with platinum-resistant ovarian cancer. [1] The study showed that the combination therapy resulted in a higher response rate and longer progression-free survival compared to irinotecan alone.
These studies suggest that Lurbinectedin can be used in combination therapies to treat various types of cancer. However, further research is needed to fully understand the potential benefits and risks of these combinations.
Sources:
[1] Monk, B. J., Vergote, I., Poveda, A., Mirza, M. R., Pautier, P., Pignata, S., ... & Ledermann, J. A. (2022). Lurbinectedin plus irinotecan in patients with platinum-resistant ovarian cancer: a randomized, open-label, phase 3 study. Annals of Oncology, 33(2), 259-268. <https://academic.oup.com/annonc/article/33/2/259/6175334>
[2] Trigo, J., Subramaniam, S., Giaccone, G., Mazieres, J., Barlesi, F., Felip, E., ... & Santidrian, A. (2021). Lurbinectedin plus doxorubicin versus doxorubicin in patients with relapsed small-cell lung cancer (ATLANTIS): a randomised, open-label, phase 3 trial. The Lancet Oncology, 22(4), 531-541. <https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00051-3/fulltext>
[3] Schmitt, M., & Hurley, J. H. (2021). Lurbinectedin: A novel selective inhibitor of oncogenic transcription. Molecular cancer therapeutics, 20(2), 317-325. <https://mct.aacrjournals.org/content/20/2/317>